Trial · NCT03118739
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
61 to 80 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Urinalysis | Verinurad 9 mg+Febuxostat 80 mg | Urine Urate, mg/dL 12 weeks (CFB) | -13.394 | Standard Deviation 13.2757 | mg/dL |
| Urinalysis | Placebo | Urine Urate, mg/dL 12 weeks (CFB) | 3.560 | Standard Deviation 12.3875 | mg/dL |
| Urinalysis | Verinurad 9 mg+Febuxostat 80 mg | Urine Urate, mg/dL 24 weeks (CFB) | -10.732 | Standard Deviation 16.4720 | mg/dL |
| Urinalysis | Placebo | Urine Urate, mg/dL 24 weeks (CFB) | 2.294 | Standard Deviation 9.3407 | mg/dL |
| Clinical Chemistry Values | Verinurad 9 mg+Febuxostat 80 mg | Baseline Aldosterone, pmol/L | 134.58 | Standard Deviation 126.126 | pmol/L |
| Clinical Chemistry Values | Placebo | Baseline Aldosterone, pmol/L | 95.11 | Standard Deviation 72.640 | pmol/L |
| Clinical Chemistry Values | Verinurad 9 mg+Febuxostat 80 mg | Aldosterone, pmol/L 12 weeks (CFB) | 1.12 | Standard Deviation 118.622 | pmol/L |
| Clinical Chemistry Values | Placebo | Aldosterone, pmol/L 12 weeks (CFB) | 14.72 | Standard Deviation 72.485 | pmol/L |
| Clinical Chemistry Values | Verinurad 9 mg+Febuxostat 80 mg | Aldosterone, pmol/L 24 weeks (CFB) | 9.14 | Standard Deviation 102.932 | pmol/L |
| Clinical Chemistry Values | Placebo | Aldosterone, pmol/L 24 weeks (CFB) | 38.14 | Standard Deviation 90.007 | pmol/L |
| Clinical Chemistry Values | Verinurad 9 mg+Febuxostat 80 mg | Baseline NT-proBNP, pmol/L | 23.230 | Standard Deviation 22.6864 | pmol/L |
| Clinical Chemistry Values | Placebo | Baseline NT-proBNP, pmol/L | 15.866 | Standard Deviation 28.2147 | pmol/L |
| Clinical Chemistry Values | Verinurad 9 mg+Febuxostat 80 mg | NT-proBNP, pmol/L 12 weeks (CFB) | 4.621 | Standard Deviation 31.1027 | pmol/L |
| Clinical Chemistry Values | Placebo | NT-proBNP, pmol/L 12 weeks (CFB) | 1.556 | Standard Deviation 10.0140 | pmol/L |
| Clinical Chemistry Values | Verinurad 9 mg+Febuxostat 80 mg | NT-proBNP, pmol/L 24 weeks (CFB) | 6.267 | Standard Deviation 19.0367 | pmol/L |
| Clinical Chemistry Values | Placebo | NT-proBNP, pmol/L 24 weeks (CFB) | 15.866 | Standard Deviation 46.4392 | pmol/L |
| Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo | Verinurad 9 mg+Febuxostat 80 mg | -49.26 | 90% Confidence Interval -68.206 to -19.009 | Precent change | |
| Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo | Placebo | NA | 90% Confidence Interval NA to NA | Precent change | |
| MRI Variables - Kidney Cortex T2 Star - BOLD MRI | Verinurad 9 mg+Febuxostat 80 mg | -1.46 | Standard Deviation 6.511 | ms | |
| MRI Variables - Kidney Cortex T2 Star - BOLD MRI | Placebo | -1.67 | Standard Deviation 6.440 | ms |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03118739/results?page=4